(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 26.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Ionis Pharmaceuticals's revenue in 2026 is $943,711,000.On average, 25 Wall Street analysts forecast IONS's revenue for 2026 to be $140,842,708,579, with the lowest IONS revenue forecast at $111,189,090,684, and the highest IONS revenue forecast at $169,487,003,286. On average, 22 Wall Street analysts forecast IONS's revenue for 2027 to be $234,407,463,609, with the lowest IONS revenue forecast at $160,239,554,510, and the highest IONS revenue forecast at $343,599,382,880.
In 2028, IONS is forecast to generate $312,543,284,812 in revenue, with the lowest revenue forecast at $215,740,766,366 and the highest revenue forecast at $411,328,107,390.